Telaprevir Experience From Turkey

KÖMÜR S., KURTARAN B., İNAL A. S., PULLUKÇU H., ULU A., Kuscu F., ...Daha Fazla

HEPATITIS MONTHLY, cilt.15, sa.2, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 2
  • Basım Tarihi: 2015
  • Doi Numarası: 10.5812/hepatmon.25639
  • Dergi Adı: HEPATITIS MONTHLY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: In patients with chronic hepatitis C, triple drug regimens containing a protease inhibitor, peginterferon and ribavirin were found to significantly increase sustained virologic response rates compared to dual drug regimen containing pegylated interferon and ribavirin, especially in genotype 1.